Latest news with #fattyliverdisease
Reuters
26-06-2025
- Health
- Reuters
Altimmune's weight-loss drug meets main goal in fatty liver disease trial
June 26 (Reuters) - Altimmune (ALT.O), opens new tab said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease. The drug, pemvidutide, showed a subsiding of metabolic dysfunction-associated steatohepatitis (MASH), or non-alcoholic steatohepatitis (NASH), without a worsening of liver scarring in up to 59.1% of participants in the 212-patient trial. A weight loss of up to 6.2% was also seen in the trial. Despite the positive results, shares were down 56% premarket. Pemvidutide is being studied separately as an obesity treatment.
Reuters
20-06-2025
- Health
- Reuters
EU medicines regulator grants conditional authorisation for Madrigal's liver disease drug
June 20 (Reuters) - The European Union's medicines regulator on Friday granted a conditional authorisation for Madrigal Pharmaceuticals' (MDGL.O), opens new tab drug for a type of fatty liver disease, paving the way to make it the first treatment available for the condition in the region. The drug, sold as Rezdiffra, was first approved in the United States in March last year. The disease known as non-alcoholic steatohepatitis (NASH), or more recently renamed as metabolic dysfunction-associated steatohepatitis (MASH), causes excess build up of fat in the liver, resulting in inflammation and fibrosis, or scarring, of the organ.
Yahoo
14-06-2025
- Health
- Yahoo
Scientists make new discovery that could help prevent diet-related liver cancer
New research has identified a pathway that may prevent fatty liver disease, often caused by diets high in fat and sugar, from progressing to liver cancer. Experts have noted an increase in cases of liver cancer arising from fatty liver disease. Currently, there are no effective treatments to halt the progression of fatty liver disease to liver cancer, largely due to a lack of understanding of the mechanisms involved. Researchers from Glasgow Caledonian University, the Cancer Research UK Scotland Institute, and The Francis Crick Institute previously identified the tumour suppressor gene p53 as crucial for protecting the liver against toxins. They have now discovered that p53 also shields the liver from the harmful effects of high-fat, high-sugar diets through a gene called TIGAR. TIGAR acts as an antioxidant and detoxifies lipids in a fatty liver. Experts said the breakthrough suggests antioxidant therapy could be developed to mimic the protective response of p53 and TIGAR, which would prevent the development of some of the key features of fatty liver disease. Dr Timothy Humpton, who leads the 'Liver p53 lab' at Glasgow Caledonian University, worked on the research paper with his PhD student Celine Wittke, who is co-first author with Dr Eric Cheung, from The Francis Crick Institute. Dr Humpton said: 'This research has established a key role for p53 and TIGAR in protecting against the progression from liver disease to liver cancer. Targeting this through the use of antioxidants is of great interest for future therapies aiming to prevent liver cancer. 'Many people still don't realise that a bad diet full of fat and sugar, and the lack of exercise, can actually cause fatty liver disease which can progress to liver cancer, so it's not just people who drink alcohol that are susceptible.' 'Fatty liver disease is hard to diagnose because it's asymptomatic for the most part. 'That's why liver cancer prognosis is so poor in these patients. It's frequently not flagged until it's advanced cancer. 'We are hoping that an antioxidant therapy can be developed through the results of our p53 and TIGAR research to help reverse some of the damage done to the liver by the Western diet high in fat and sugar.' The research is published in JHep Reports, a leading journal in the field of Gastroenterology and Hepatology. Click below to see the latest Scotland headlines
The Independent
11-06-2025
- Health
- The Independent
The therapy that could help prevent food-related liver cancer
New research has identified a pathway involving the genes p53 and TIGAR that may prevent fatty liver disease from progressing to liver cancer, a condition for which there are currently no effective treatments. Researchers from Glasgow Caledonian University, the Cancer Research UK Scotland Institute, and The Francis Crick Institute discovered that p53 protects the liver from high-fat, high-sugar diets through the gene TIGAR, which acts as an antioxidant and detoxifies lipids in a fatty liver. The breakthrough suggests that antioxidant therapy could be developed to mimic the protective response of p53 and TIGAR, potentially preventing the development of key features of fatty liver disease. Dr. Timothy Humpton noted that the research establishes a key role for p53 and TIGAR in protecting against the progression from liver disease to liver cancer, suggesting that targeting this pathway through antioxidants is of great interest for future therapies. He also highlighted that fatty liver disease, often caused by poor diet and lack of exercise, is hard to diagnose due to its asymptomatic nature.
WebMD
10-06-2025
- Health
- WebMD
Meet Our Hosts on MASLD and MASH
In his 40s, Álvarez was diagnosed with fatty liver disease. Genetics can play a role, and he later learned that his mother had the same condition. "Navigating this journey has deepened my understanding of resilience and the importance of health," he says. He spreads awareness of the serious liver damage that has deeply affected his life. Originally from Nicaragua, his passions lie in film, theater, and music. Lance Stein, MD An expert in treating MASLD and MASH, Stein is a transplant hepatologist. He's the medical director of Piedmont Healthcare's hepatology and liver transplant program. He's also a clinical assistant professor of medicine at Mercer University.
